Intech Investment Management LLC Decreases Holdings in AbbVie Inc. $ABBV

Intech Investment Management LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 26.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,533 shares of the company’s stock after selling 25,923 shares during the quarter. Intech Investment Management LLC’s holdings in AbbVie were worth $16,331,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Ellenbecker Investment Group grew its stake in shares of AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after purchasing an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA boosted its holdings in shares of AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after buying an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC boosted its holdings in shares of AbbVie by 0.3% in the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after buying an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC grew its position in AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after buying an additional 45 shares during the period. Finally, Willner & Heller LLC increased its holdings in AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after buying an additional 46 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $380 million investment to build two new API (active pharmaceutical ingredient) manufacturing facilities at its North Chicago campus — a multi‑year project expected to boost U.S. supply security, support production for obesity and other franchises, and create several hundred jobs (facilities targeted to be operational by 2029). AbbVie to build 2 API plants in Illinois
• Positive Sentiment: The FDA approved the VENCLEXTA (venetoclax) + acalabrutinib combination for first‑line treatment of CLL — the first all‑oral, fixed‑duration regimen for previously untreated patients, which should expand market opportunity and support oncology revenue growth. FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and a $275 price target, citing upside from operating leverage and under‑appreciated growth potential — a note that can improve sentiment among institutional investors. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in Bipolar I disorder — supportive real‑world evidence can aid uptake, but the near‑term revenue impact is limited. AbbVie’s Real‑World Vraylar Study in Bipolar I Disorder Reaches Completion
• Neutral Sentiment: AbbVie will present at the TD Cowen Health Care Conference on March 3 — a routine investor event that could provide incremental disclosure but not guaranteed news. AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Multiple retail and dividend‑oriented writeups are highlighting AbbVie’s high yield and growing payout — this supports income‑investor interest but is unlikely to move the stock materially on its own. This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
• Negative Sentiment: Analysts and research notes flag execution risk and intensifying competition across parts of AbbVie’s pipeline and immunology portfolio — these concerns are constraining upside in some models and tempering investor enthusiasm. How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative
• Negative Sentiment: Valuation and momentum considerations (ABBV trades with a high P/E and recently near its 52‑week range) plus below‑average intraday volume can prompt profit‑taking even when company news is constructive.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent research reports. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Scotiabank assumed coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target for the company. BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research note on Thursday, January 15th. Berenberg Bank set a $275.00 price objective on AbbVie in a research report on Tuesday, January 20th. Finally, Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Price Performance

Shares of ABBV opened at $227.01 on Thursday. The firm has a market cap of $401.38 billion, a P/E ratio of 96.19, a price-to-earnings-growth ratio of 0.79 and a beta of 0.35. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a 50 day simple moving average of $224.22 and a two-hundred day simple moving average of $222.70.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the previous year, the firm posted $2.16 EPS. AbbVie’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.